title: Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis.
abstract: Decoy receptor 3 (DcR3) is associated with autoimmunity and altered angiogenesis in certain pathological conditions. We herein measured serum DcR3 levels in 51 patients with systemic sclerosis (SSc) and 19 healthy controls and evaluated their clinical significance in this disorder. Serum DcR3 levels were significantly higher in diffuse cutaneous SSc (dcSSc) patients than in limited cutaneous SSc patients and in healthy controls. In dcSSc, serum DcR3 levels were significantly elevated in patients with disease duration of ≤6 years compared with healthy controls, but not in those with disease duration of >6 years. Serum DcR3 levels correlated negatively with the percentage of predicted diffusion lung capacity for carbon monoxide and positively with right ventricular systolic pressure. Furthermore, serum DcR3 levels positively correlated with C-reactive protein, erythrocyte sedimentation rate and immunoglobulin G. Collectively, the elevation of serum DcR3 levels is associated with the development of pulmonary arterial hypertension and systemic inflammation in SSc.
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yamada
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asano
authors.forename: Takehiro
authors.initials: T
authors.lastname: Takahashi
authors.forename: Yuri
authors.initials: Y
authors.lastname: Masui
authors.forename: Naohiko
authors.initials: N
authors.lastname: Aozasa
authors.forename: Kaname
authors.initials: K
authors.lastname: Akamata
authors.forename: Shinji
authors.initials: S
authors.lastname: Noda
authors.forename: Zenshiro
authors.initials: Z
authors.lastname: Tamaki
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Tada
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugaya
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
authors.forename: Takafumi
authors.initials: T
authors.lastname: Kadono
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001799:Blood Sedimentation; D000077300:Bosentan; D002097:C-Reactive Protein / Q000032:analysis; D015897:Comorbidity; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000453:epidemiology; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017563:Lung Diseases, Interstitial / Q000097:blood / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000097:blood*; D012595:Scleroderma, Systemic / Q000097:blood* / Q000453:epidemiology; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053323:Receptors, Tumor Necrosis Factor, Member 6b; D013449:Sulfonamides; D003520:Cyclophosphamide; D002097:C-Reactive Protein; D000077300:Bosentan